Phase 3Completed
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
- Sponsor
- AbbVie (Industry)
- Enrollment
- 691 enrolled
- Conditions
- Glioblastoma; Gliosarcoma
- Interventions
- Temozolomide; Depatuxizumab mafodotin; Radiation; Placebo for ABT-414
- Ages
- adults, older adults
- Registry
- NCT02573324, EUCTR2015-001166-26
Full record on ClinicalTrials.gov
From the registry
This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) followed by combination of ABT-414 with adjuvant TMZ prolongs overall survival (OS) among participants with newly diagnosed glioblastoma (GBM) with epidermal growth factor receptor (EGFR) amplification. In addition, there is a Phase 1, open-label, multicenter sub-study to assess the pharmacokinetics, safety and tolerability of ABT-414 in participants with newly diagnosed EGFR-amplified GBM who have mild or moderate hepatic impairment.
Primary outcomes
- Overall Survival (OS)
History
Results first posted
Last registry update
Primary completion
Registered
Started